Brendan Doyle

5.4k total citations · 1 hit paper
56 papers, 3.5k citations indexed

About

Brendan Doyle is a scholar working on Molecular Biology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brendan Doyle has authored 56 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 18 papers in Surgery and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brendan Doyle's work include Renal Diseases and Glomerulopathies (8 papers), Coronary Interventions and Diagnostics (5 papers) and Cancer-related Molecular Pathways (5 papers). Brendan Doyle is often cited by papers focused on Renal Diseases and Glomerulopathies (8 papers), Coronary Interventions and Diagnostics (5 papers) and Cancer-related Molecular Pathways (5 papers). Brendan Doyle collaborates with scholars based in Ireland, United States and United Kingdom. Brendan Doyle's co-authors include Noel M. Caplice, Charanjit S. Rihal, Owen J. Sansom, David R. Holmes, Saadia A. Karim, Dennis A. Gastineau, Jennifer P. Morton, Karin A. Oien, Nigel B. Jamieson and Ryan J. Lennon and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Brendan Doyle

54 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutant p53 Drives Invasion by Promoting Integrin Recycling

2009 641 citations Patricia Müller, Patrick T. Caswell et al. Cell profile →

Peers

Countries citing papers authored by Brendan Doyle

Since Specialization

Citations

This map shows the geographic impact of Brendan Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan Doyle more than expected).

Fields of papers citing papers by Brendan Doyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan Doyle. The network helps show where Brendan Doyle may publish in the future.

Co-authorship network of co-authors of Brendan Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of Brendan Doyle. A scholar is included among the top collaborators of Brendan Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan Doyle. Brendan Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acute kidney Injury due to Alectinib, an Anaplastic Lymphoma Kinase inhibitor 2021 ·(unknown), (unknown), (unknown), Sinéad Cuffe, Brendan Doyle, Brenda Walker Griffin, Donal J. Sexton	0
2	Diagnostic utility of genetic testing in patients undergoing renal biopsy 2020 ·Molecular Case Studies ·Katherine A. Benson, Susan Murray, Ross Doyle, Brendan Doyle, Anthony Dorman, Denise M. Sadlier, Eoin Brennan, Margaret Large, Gianpiero L. Cavalleri, Catherine Godson, Peter J. Conlon	8
3	Progressive improvement in short‐, medium‐ and long‐term graft survival in kidney transplantation patients in Ireland – a retrospective study 2019 ·Transplant International ·Donal J. Sexton, Patrick O’Kelly, Yvonne Williams, William D. Plant, Mary T. Keogan, (unknown), Brendan Doyle, Anthony Dorman, Caner Süsal, Christian Unterrainer, James Forde, Richard Power, Gordon Smith, Ponnusamy Mohan, Mark Denton, Colm Magee, D.G. de Freitas, Dilly Little, Conall M. O’Seaghdha, Peter J. Conlon	10
4	Utility of Genomic Testing after Renal Biopsy 2019 ·American Journal of Nephrology ·Susan Murray, Anthony Dorman, Katherine A. Benson, Dervla M. Connaughton, Caragh P. Stapleton, (unknown), Claire Kennedy, (unknown), Kendrah Kidd, Sarah Cormican, (unknown), Peter Lavin, Mark A. Little, Anthony J. Bleyer, Brendan Doyle, Gianpiero L. Cavalleri, Friedhelm Hildebrandt, Peter J. Conlon	19
5	Karyomegalic Interstitial Nephritis: Cancer Risk Following Transplantation 2019 ·The Nephron journals/Nephron journals ·Susan Murray, Dervla M. Connaughton, (unknown), Elaine W. Kay, (unknown), Brendan Doyle, Peter J. Conlon	7
6	Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett’s Esophagus Compared to Esophageal Adenocarcinoma 2019 ·International Journal of Molecular Sciences ·Naoimh J. O’Farrell, J.J. Phelan, (unknown), Brendan Doyle, Sarah Picardo, Narayanasamy Ravi, Dermot O’Toole, John V. Reynolds, Jacintha O’Sullivan	20
7	HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients 2017 ·Cancer Immunology Immunotherapy ·Margaret R. Dunne, (unknown), Katie E. O’Sullivan, (unknown), (unknown), Brendan Doyle, Jenny Watson, Naoimh J. O’Farrell, Narayanasamy Ravi, Elaine W. Kay, John V. Reynolds, Elizabeth J. Ryan, Jacintha O’Sullivan	34
8	Targeted therapies in colorectal cancer—an integrative view by PPPM 2013 ·The EPMA Journal ·Suzanne Hagan, Maria Orr, Brendan Doyle	65
9	Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53 2011 ·Cancer Research ·Paul Timpson, Ewan J. McGhee, Jennifer P. Morton, Alex von Kriegsheim, Juliane P. Schwarz, Saadia A. Karim, Brendan Doyle, Jean A. Quinn, Neil O. Carragher, Mike Edward, Michael F. Olson, Margaret C. Frame, Valerie G. Brunton, Owen J. Sansom, Kurt I. Anderson	109
10	Raf Kinase Inhibitor Protein RKIP Enhances Signaling by Glycogen Synthase Kinase-3β 2011 ·Cancer Research ·Fahd Al‐Mulla, Milad S. Bitar, May Al‐Maghrebi, A. Behbehani, Waleed Al-Ali, Oliver Rath, Brendan Doyle, (unknown), Andrew R. Pitt, Walter Kölch	96
11	Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis 2011 ·Molecular Cell ·Alyssa L. Kennedy, Jennifer P. Morton, (unknown), David M. Nelson, Nigel B. Jamieson, Jeff S. Pawlikowski, Tony McBryan, Brendan Doyle, Colin J. McKay, Karin A. Oien, Greg H. Enders, Rugang Zhang, Owen J. Sansom, Peter D. Adams	160
12	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer 2009 ·Proceedings of the National Academy of Sciences ·Jennifer P. Morton, Paul Timpson, Saadia A. Karim, Rachel A. Ridgway, Dimitris Athineos, Brendan Doyle, Nigel B. Jamieson, Karin A. Oien, Andrew M. Lowy, Valerie G. Brunton, Margaret C. Frame, T.R. Jeffry Evans, Owen J. Sansom	465
13	Mutant p53 Drives Invasion by Promoting Integrin Recycling breakdown → 2009 ·Cell ·Patricia Müller, Patrick T. Caswell, Brendan Doyle, Marcin Iwanicki, Ee Hong Tan, Saadia A. Karim, Natalia Lukashchuk, David A. Gillespie, Robert L. Ludwig, Pauline Gosselin, Anne Cromer, Joan S. Brugge, Owen J. Sansom, Jim C. Norman, Karen H. Vousden	641
14	A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model 2008 ·Carcinogenesis ·Bryan Serrels, Alan Serrels, Susan Mason, Christine Baldeschi, G H S Ashton, Marta Canel, Lorna Mackintosh, Brendan Doyle, Tim P. Green, Margaret C. Frame, Owen J. Sansom, Valerie G. Brunton	28
15	Progenitor Cell Therapy in a Porcine Acute Myocardial Infarction Model Induces Cardiac Hypertrophy, Mediated by Paracrine Secretion of Cardiotrophic Factors Including TGFβ1 2008 ·Stem Cells and Development ·Brendan Doyle, Paul Sorajja, Brian Hynes, Arun Kumar, Phillip A. Araoz, Paul G. Stalboerger, Dylan V. Miller, (unknown), Jeffrey Schmeckpeper, Shaohua Wang, Chunsheng Liu, André Terzic, (unknown), Stephen J. Riederer, Noel M. Caplice	58
16	Clinical trials in stem cell therapy: pitfalls and lessons for the future 2007 ·Nature Clinical Practice Cardiovascular Medicine ·Pat Metharom, Brendan Doyle, Noel M. Caplice	6
17	Frequency, Etiology, Treatment, and Outcomes of Drug-Eluting Stent Thrombosis During One Year of Follow-Up 2006 ·The American Journal of Cardiology ·Gurpreet S. Sandhu, Brendan Doyle, (unknown), Malcolm R. Bell, John F. Bresnahan, Verghese Mathew, David R. Holmes, Amir Lerman, Charanjit S. Rihal	21
18	Endothelial Progenitor Cells 2006 ·Endothelium ·Brendan Doyle, Pat Metharom, Noel M. Caplice	36
19	Vascular Progenitor Cells: Origin and Mechanisms of Mobilization, Differentiation, Integration, and Vasculogenesis 2005 ·Stem Cells and Development ·Noel M. Caplice, Brendan Doyle	56
20	A new source of endothelial progenitor cells – vascular biology redefined? 2005 ·Trends in biotechnology ·Brendan Doyle, Noel M. Caplice	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact